
Andrea Ruth Hagemann MD
Gynecologic Oncology
Gynecologic Oncology
Join to View Full Profile
4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 314-362-3181
Fax+1 314-362-2893
Dr. Hagemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
- Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 2004 - 2008
- Washington University in St. Louis School of MedicineClass of 2004
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2011 - 2026
- PA State Medical License 2008 - 2012
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Start of enrollment: 2016 Jan 01
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Start of enrollment: 2021 Apr 09
Publications & Presentations
PubMed
- Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.Angela Schab, Amanda Compadre, Rebecca Drexler, Megan Loeb, Kevin Rodriguez
The Journal of Clinical Investigation. 2025-07-01 - OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed...Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed
Gynecologic Oncology. 2025-06-01 - Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.David H Morris, Alison Kosmacki, Leah Tolby, Christine Marx, Jessica Vanderlan
Gynecologic Oncology. 2025-05-01
Journal Articles
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous CancerIan S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research
Press Mentions
- Medical Students Celebrate Their Teachers, MentorsNovember 19th, 2019
- Case Series Do Gynecologic Oncology Patients with Severely Diminished Renal Function and Urinary Tract Obstruction Benefit from Ureteral Stenting or Percutaneous Nephrostomy?May 12th, 2019
- $11.6 Million Grant Supports Innovative Research in Endometrial Cancer – Washington University School of Medicine in St. LouisSeptember 7th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: